Healthcare Industry News: Rinspiration
News Release - June 27, 2006
Peripheral Rinspiration(R) Catheter System Prominently Featured at Mount Sinai Live Cardiovascular SymposiumRinspiration Used Pre- and Post-Intervention in a Total Occlusion to Revascularize Blood Flow in 73-Year-Old Patient
CUPERTINO, Calif.--(HSMN NewsFeed)--June 27, 2006--The continued success of the Kerberos Peripheral Rinspiration® Catheter System in multi-device treatment interventions was one of the showcases highlighted at the IX Live Symposium of Complex Coronary and Cardiovascular Cases in New York June 14-17.
Rinspiration is an innovative technology that delivers physician-specified fluids to simultaneously rinse and aspirate embolic debris and thrombus out to the vessel wall. The combined action is unique to Rinspiration, and helps prevent debris from potentially moving downstream and putting patients at risk of peripheral occlusions within the microvasculature.
The symposium, hosted by the Cardiovascular Institute of Mt. Sinai, under the directorship of Dr. Samin K. Sharma, used live case presentations as a platform to discuss state-of-the-art interventional technologies now being used to manage complex and challenging patient anatomies targeted for revascularization.
In the case conducted by Dr. Prakash Krishnan of Mt. Sinai Medical Center, Rinspiration was used as part of a multi-device interventional effort to re-establish blood flow in a 73-year-old patient with total occlusion of the superficial femoral artery. "The patient had a particularly diseased and calcified vessel that required a multi-device approach," said Dr. Krishnan. "The simultaneous rinsing and aspiration delivered by the Rinspiration System was instrumental in removing a large volume of thrombus, which helped us to identify specifically the location of the stenotic lesion. Better visualization allowed further treatment with atherectomy and balloon angioplasty, followed by stent placement."
Dr. Krishnan continued, "Rinspirating post-intervention reduced the risk of distal embolization from any calcified debris that dislodged from the interior arterial lumen due to wall contact. Flow was successfully re-established all the way to the patient's foot. I was particularly satisfied with how well the Rinspiration System performed in this very challenging patient case."
The Rinspiration System is designed to administer physician-prescribed fluids and remove thrombi (blood clots) and emboli (debris) from the peripheral and coronary vasculature. For debris removal, Rinspiration is an important asset when a multi-interventional approach (angioplasty, stent, atherectomy, drug therapy, laser) is used to treat a partial or total occlusion in the lower extremity. Rinspiration is also used pre- and post-coronary intervention.
Dr. Donald S. Baim, Brigham and Women's Hospital in Boston, presented a case where Rinspiration was used in the treatment of a mid-right acute coronary case. "Rinspiration is used proximal to distal; you don't have to cross the thrombus and the underlying friable lesion to remove it," said Dr. Baim.
Up to 12 million people in the United States are afflicted with peripheral arterial disease, while some 13 million suffer from coronary artery disease. The most common form of both disease states involves plaque buildup on the interior artery wall that can eventually lead to reduced blood flow and development of a blood clot.
About Kerberos Proximal Solutions Inc.
Kerberos Proximal Solutions Inc. is a privately held medical device company headquartered in Cupertino, Calif. Founded in 2001, Kerberos is dedicated to developing innovative solutions to treat vascular disease. Investors in Kerberos include Three Arch Partners, Boston Scientific Corp. (NYSE: BSX ) and Research Corp. Technologies. For additional information, contact King Nelson at 408-253-3319.
About The Cardiovascular Institute of Mount Sinai, go to http://www.mssm.edu/cvi.
Source: Kerberos Proximal Solutions
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.